Open an account

Neogenomics

NEO · NASDAQ

$16.62+$0.20 (+1.22%)TodayMarket closed ·
Prev close $16.42

About NEO

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,500 full-time employees. The company went IPO on 2012-12-10. The firm offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. The company operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.

Employees
2,500
Headquarters
Fort Myers, Florida
Listed
Dec 10, 2012
Sector
Health Care
Industry
Health Care Providers & Services
Website
neogenomics.com

NEO key statistics

Market cap
2.14B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.42M
Volume
1.10M
Open price
$16.55
High today
$16.92
Low today
$16.39
52 Week high
$20.15
52 Week low
$7.07

Neogenomics (NEO) at a glance

As of Oct 20, 2026, Neogenomics (NEO) shares are priced at $16.62, giving the company a market cap of 2.14B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $16.39 and $16.92. The current price is 1.4% above the day's low and 1.8% below its high.

Volume so far is 1.10M shares, below the average of 2.42M shares a day.

Over the past year Neogenomics has ranged from $7.07 to $20.15, and now sits 73% of the way up that range.

Neogenomics met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $0.05 per share against an estimate of $0.0331.

The average analyst price target is $20.12, 21.0% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 7 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $20.12
Low
$16.16
Now
$16.62
High
$36.75

NEO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 81.0% on average.

  1. Q3 FY24: reported $0.05 per share against an estimate of $0.0126
  2. Q4 FY24: reported $0.04 per share against an estimate of $0.0296
  3. Q1 FY25: reported $0.00 per share against an estimate of -$0.012
  4. Q2 FY25: reported $0.03 per share against an estimate of $0.0228
  5. Q3 FY25: reported $0.03 per share against an estimate of $0.0213
  6. Q4 FY25: reported $0.06 per share against an estimate of $0.0391
  7. Q1 FY26: reported $0.01 per share against an estimate of $0.0072
  8. Q2 FY26: reported $0.05 per share against an estimate of $0.0331

NEO news

  • Press releaseBusiness Wire

    NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology

  • Press releaseBusiness Wire

    NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026

  • Vandana Singh

    What's Going On With NeoGenomics Stock Tuesday?

  • Press releaseBusiness Wire

    NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan

  • Press releaseBusiness Wire

    NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

  • Press releaseBusiness Wire

    NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring

  • Vandana Singh

    Greenland Mines Outlines $2B Valuation for Sarfartoq Project

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Similar companies

Companies in the same industry as Neogenomics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.